These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 23919663

  • 1. Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
    Fanikos J.
    J Med Econ; 2013 Oct; 16(10):1190-2. PubMed ID: 23919663
    [No Abstract] [Full Text] [Related]

  • 2. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Koziński M, Obońska K, Kubica A, Navarese EP, Kubica J.
    Kardiol Pol; 2012 Oct; 70(10):1053-60. PubMed ID: 23080100
    [No Abstract] [Full Text] [Related]

  • 3. New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
    Barry M.
    Ir Med J; 2013 Mar; 106(3):69. PubMed ID: 23951972
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA.
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [Abstract] [Full Text] [Related]

  • 5. Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
    Harris K, Mant J.
    Int J Clin Pract; 2013 Jul; 67(7):647-55. PubMed ID: 23621153
    [Abstract] [Full Text] [Related]

  • 6. New directions in anticoagulation.
    Alpert JS.
    Am J Med; 2012 Mar; 125(3):217-8. PubMed ID: 22340912
    [No Abstract] [Full Text] [Related]

  • 7. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP, Halperin JL.
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Harrington AR, Armstrong EP, Nolan PE, Malone DC.
    Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
    [Abstract] [Full Text] [Related]

  • 10. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [Abstract] [Full Text] [Related]

  • 11. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A, Al-Majzoub O, Kanaan AO, Donovan JL, Silva M.
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [Abstract] [Full Text] [Related]

  • 12. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
    Testa L, Agnifili M, Latini RA, Mattioli R, Lanotte S, De Marco F, Oreglia J, Latib A, Pizzocri S, Laudisa ML, Brambilla N, Bedogni F.
    QJM; 2012 Oct; 105(10):949-57. PubMed ID: 22771555
    [Abstract] [Full Text] [Related]

  • 13. Oral anticoagulants: the move beyond warfarin.
    Frei J, Carroll VS.
    J Neurosci Nurs; 2014 Oct; 46(5):253-5. PubMed ID: 25188682
    [No Abstract] [Full Text] [Related]

  • 14. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
    Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.
    J Med Econ; 2012 Oct; 15(4):776-85. PubMed ID: 22449118
    [Abstract] [Full Text] [Related]

  • 15. [New anticoagulants--should we have a little bit of cold water in the blood?].
    Dyrkorn R, Roland PD.
    Tidsskr Nor Laegeforen; 2013 Feb 19; 133(4):390-1. PubMed ID: 23423204
    [No Abstract] [Full Text] [Related]

  • 16. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.
    J Med Econ; 2014 Aug 19; 17(8):587-98. PubMed ID: 24831811
    [Abstract] [Full Text] [Related]

  • 17. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY, Kim RB.
    Can J Cardiol; 2013 Jul 19; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [Abstract] [Full Text] [Related]

  • 18. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 19; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Shah SV, Gage BF.
    Circulation; 2011 Jun 07; 123(22):2562-70. PubMed ID: 21606397
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
    Verhoef TI, Redekop WK, Hasrat F, de Boer A, Maitland-van der Zee AH.
    Am J Cardiovasc Drugs; 2014 Dec 07; 14(6):451-62. PubMed ID: 25326294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.